New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 25, 2014
16:04 EDTIMDZImmune Design announces filing of new lawsuit by Theravectys SA
Immune Design announced that the day after it began trading on the Nasdaq Global Market, Theravectys SA, or TVS, filed a lawsuit against the company repeating claims that it had made in a prior lawsuit which TVS had earlier voluntarily dismissed. TVS alleges that it has a contractual relationship with a Belgian manufacturer, Henogen, SA, which contained an exclusivity provision limiting Henogen's ability to manufacture certain lentiviral vectors for third parties and a provision preventing Henogen from sharing or using certain TVS confidential technology related to manufacturing processes developed by TVS with or for the benefit of others. TVS asserts that the company induced Henogen to breach its exclusivity obligations by manufacturing and supplying clinical batches of lentiviral vectors to the company and seeks monetary damages, as well as injunctive relief. TVS raises claims of tortious interference with contractual relations, misappropriation of trade secrets, unfair competition and unjust enrichment. The company is not currently using Henogen to manufacture its lentiviral vectors for its clinical trials. The company developed its own vector manufacturing process that it previously transferred to Henogen, and did not have any knowledge of TVS' processes. The company believes this lawsuit is without merit and intends to vigorously defend it.
News For IMDZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 26, 2015
11:27 EDTIMDZImmune Design to hold an investor and analyst event
Subscribe for More Information
May 15, 2015
10:01 EDTIMDZOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:28 EDTIMDZImmune Design initiated with an Outperform at Cowen
Subscribe for More Information
May 14, 2015
06:03 EDTIMDZImmune Design reports Q1 EPS (56c), consensus (64c)
Reports Q1 revenue $1.94M, consensus $1.30M

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use